🇺🇸 FDA
Patent

US 9309535

Combination anti-HIV vectors, targeting vectors, and methods of use

granted A61KA61K31/7105A61K38/53

Quick answer

US patent 9309535 (Combination anti-HIV vectors, targeting vectors, and methods of use) held by The Regents of the University of California expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/7105, A61K38/53, A61K48/0066, A61P